Section B

Multi Omics-Technologies

Integration of Innovative Modern Omics-Technologies

Multi-omics characterization that deepens patient stratification and de-risks trial design.

The layers we characterize

OmicsAI – Fields of Data Generation.

Genome Transcriptome Proteome Metabolome Environmental influences Phenotype
Omics profiling

Terms, definitions and technologies

TermDefinitionCommon Technologies and Techniques
GenomicsFocuses on the structure, function, evolution, mapping, and editing of information coded within an organism’s DNA (the genome).NGS: whole-genome sequencing, exome sequencing, targeted sequencing; Microarrays
EpigenomicsThe study of how cells control gene activity through non-genetic modifications like DNA methylation and histone modification.NGS: methylation sequencing, ChIP-Seq, ATAC-Seq, HiC/3C; Microarrays: methylation arrays
TranscriptomicsThe study of the transcriptome, the set of RNA transcripts that are produced by the genome, and how it is altered in response to regulatory processes, splicing, disease, or other phenomena.NGS: mRNA-seq, whole transcriptome, and targeted RNA sequencing
ProteomicsCharacterize and identify protein expression patterns in response to specific stimuli or following genomic or transcriptomic changes.Mass spectrometry; Mass cytometry; NGS-based protein detection (e.g. SOMAmer reagents, CITE-Seq, BEN-Seq, Olink, Ab-Seq)
MetabolomicsThe study of the unique chemical fingerprints of specific cellular processes such as small-molecule metabolitesNuclear magnetic resonance; Mass spectrometry; Liquid chromatography; Gas chromatography; Supercritical fluid chromatography
Multi-Omics

Patient centric view

Helping to accelerate patient identification and simplifying clinical trials by innovative multi-omics technologies

74%

of genomic-focused researchers also use transcriptomics

  • Genomics-focused researchers
  • Transcriptomics-focused researchers
77%

of epigenetics-focused researchers also use transcriptomics

  • Epigenetics-focused researchers
  • Transcriptomics-focused researchers
66%

of transcriptomics-focused researchers also use proteomics

  • Transcriptomics-focused researchers
  • Proteomics-focused researchers
63%

of genomics-focused researchers also use proteomics

  • Genomics-focused researchers
  • Proteomics-focused researchers
53%

of epigenetics-focused researchers also use genomics

  • Epigenetics-focused researchers
  • Genomics-focused researchers
66%Patient centric view: Helping to accelerate patient identification and simplifying clinical trials by innovative multi-omics technologies
48%Year-to-year grant funding growth for multi-omics since 2012
1 out of 4 researchers say they plan to start multi-omics in the next 12 months
51%Increase in the number of publications since 2012

Facts about subrosa OmicsAI Team

Global Patient Recruitment, Identification & Biomarker Programs

600,000+Rare disease patients genome database incl. retrospective, standardized clinical data with focus on early (young) patients
58+Global patient recruitment, identification & biomarker programs incl. structured analysis of 40 representative programs
48+Countries where programs were conducted
58,000+Rare disease patients recruited and genetically characterized
30+Companies with orphan drugs served
350+Peer-reviewed publications (PubMed)

Recruitment = trial enrolment · Identification = finding undiagnosed / misdiagnosed patients (incl. post-launch) · Biomarker & omics = molecular stratification

De-risk trial design with multi-omics stratification

Talk to us about multi-omics characterization for your program.